NYSE:TAK Takeda Pharmaceutical (TAK) Stock Price, News & Analysis $20.28 -0.15 (-0.71%) As of 03:34 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Takeda Pharmaceutical Stock (NYSE:TAK) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Takeda Pharmaceutical alerts:Sign Up Key Stats Today's Range$20.19▼$20.3750-Day Range$17.39▼$20.3752-Week Range$12.99▼$20.55Volume1.75 million shsAverage Volume3.00 million shsMarket Capitalization$65.00 billionP/E Ratio59.66Dividend Yield2.37%Price TargetN/AConsensus RatingModerate Buy Company Overview Takeda Pharmaceutical Company Limited is a global biopharmaceutical company headquartered in Tokyo, Japan. The company researches, develops, manufactures and commercializes medicines for patients worldwide, with a focus on areas of significant unmet medical need. Its principal therapeutic areas include gastroenterology, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Takeda’s portfolio includes treatments such as Entyvio for inflammatory bowel disease, Takhzyro for hereditary angioedema, and medicines for certain blood cancers and rare conditions. The company also develops plasma-derived therapies and vaccines, supported by research and development operations in multiple countries and commercial activities across North America, Europe, Japan and other international markets. Takeda traces its origins to 1781, when Chobei Takeda I established a traditional medicine business in Osaka. It expanded internationally through acquisitions and strategic partnerships, including its acquisition of Shire plc, completed in 2019. Takeda is led by Christophe Weber, who serves as president and chief executive officer.AI Generated. May Contain Errors. Read More Takeda Pharmaceutical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks28th Percentile Overall ScoreTAK MarketRank™: 1.379243578155 of 5 starsTakeda Pharmaceutical scored higher than 28% of companies evaluated by MarketBeat, and ranked 787th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.7 / 5Analyst RatingModerate Buy Consensus RatingTakeda Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 2 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageTakeda Pharmaceutical has only been the subject of 2 research reports in the past 90 days.Read more about Takeda Pharmaceutical's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings Growth-10.26% Earnings GrowthEarnings for Takeda Pharmaceutical are expected to decrease by -10.26% in the coming year, from $1.56 to $1.40 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Takeda Pharmaceutical is 59.66, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 27.05.Price to Earnings Ratio vs. SectorThe P/E ratio of Takeda Pharmaceutical is 59.66, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 36.61.Price to Book Value per Share RatioTakeda Pharmaceutical has a P/B Ratio of 1.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Takeda Pharmaceutical's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.10% of the float of Takeda Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverTakeda Pharmaceutical has a short interest ratio ("days to cover") of 1.09, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Takeda Pharmaceutical has recently increased by 12.69%, indicating that investor sentiment is decreasing significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldTakeda Pharmaceutical pays a meaningful dividend of 2.38%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthTakeda Pharmaceutical does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Takeda Pharmaceutical is 141.18%. Payout ratios above 75% are not desirable because they may not be sustainable.Dividend SustainabilityBased on earnings estimates, Takeda Pharmaceutical will have a dividend payout ratio of 34.29% next year. This indicates that Takeda Pharmaceutical will be able to sustain or increase its dividend.Read more about Takeda Pharmaceutical's dividend. News and Social Media2.5 / 5News Sentiment0.01 News SentimentTakeda Pharmaceutical has a news sentiment score of 0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Takeda Pharmaceutical this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for TAK on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows1 people have added Takeda Pharmaceutical to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Takeda Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,981,175.00 in company stock.Percentage Held by Insiders0.04% of the stock of Takeda Pharmaceutical is held by insiders.Percentage Held by Institutions9.17% of the stock of Takeda Pharmaceutical is held by institutions.Read more about Takeda Pharmaceutical's insider trading history. Receive TAK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TAK Stock News HeadlinesTakeda Cancer Drug Extends Survival in Phase 3 Gastric Cancer TrialOctober 23, 2026 | finance.yahoo.comTakeda Pharmaceutical Company Limited Announces Positive Results From Phase 3 G-HOPE-001 Study Of Arcotatug Tavatecan In Advanced Gastric CancerOctober 23, 2026 | marketscreener.comMFirst Look: Elon’s “Starphone”Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to be thinner, longer-lasting on battery, and cheaper to produce, with the ability to work worldwide without relying on cell towers. Former Bloomberg reporter and SAC Capital trader Josh Baylin says the evidence is mounting. He notes the FCC recently gave Musk a green light connected to his mobile plans, adding fuel to speculation. Baylin previously called the smartphone boom in 2004 and predicted Apple would sell a billion phones when others expected a fraction of that.October 27 at 1:00 AM | Stansberry Research (Ad)Takeda Pharmaceutical (TAK) Expected to Release Quarterly Earnings on ThursdayOctober 22, 2026 | americanbankingnews.comTakeda Pharmaceutical (NYSE:TAK) Sets New 12-Month High - Still a Buy?October 21, 2026 | americanbankingnews.comFirst and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related ComplicationOctober 19, 2026 | businesswire.comTakeda Pharmaceutical (NYSE:TAK) Sets New 1-Year High - What's Next?October 17, 2026 | americanbankingnews.comTakeda Pharmaceutical Launches Orzeyful in Japan and ChinaOctober 15, 2026 | finance.yahoo.comSee More Headlines TAK Stock Analysis - Frequently Asked Questions How have TAK shares performed this year? Takeda Pharmaceutical's stock was trading at $15.59 at the beginning of the year. Since then, TAK shares have increased by 30.1% and is now trading at $20.2850. How were Takeda Pharmaceutical's earnings last quarter? Takeda Pharmaceutical Co. (NYSE:TAK) announced its quarterly earnings results on Thursday, July, 30th. The company reported $0.95 earnings per share for the quarter, beating analysts' consensus estimates of $0.41 by $0.54. The business had revenue of $7.50 billion for the quarter, compared to analysts' expectations of $7.13 billion. Takeda Pharmaceutical had a trailing twelve-month return on equity of 10.95% and a net margin of 3.80%. Read the conference call transcript. Does Takeda Pharmaceutical have any subsidiaries? Takeda Pharmaceutical subsidiaries include PvP Biologics, Shire, TiGenix, ARIAD Pharmaceuticals, Inviragen, LigoCyte Pharmaceuticals, Intellikine, and others. Who are Takeda Pharmaceutical's major shareholders? Takeda Pharmaceutical's top institutional investors include Crossmark Global Holdings Inc. (0.02%), Legacy Wealth Asset Management LLC (0.01%), Quadrant Capital Group LLC and Gold Investment Management Ltd.. Insiders that own company stock include Pharmaceutical Co Ltd Takeda, Julie So-Young Kim, Giles Richard Platford, Natalie Anne Marie Furney, Lauren Rusckowski Duprey, Agosti Marcello Pignagnoli, Gabriele Ricci, Andrew Stewart Plump, Awny Samaan Botros Farajallah, Ramy Riad Ahmed Ibrahim, Elaine Mary Shannon and Nicola Deidre Petal Greenway. View institutional ownership trends. How do I buy shares of Takeda Pharmaceutical? Shares of TAK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Takeda Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Takeda Pharmaceutical investors own include NVIDIA (NVDA), Pfizer (PFE), Verizon Communications (VZ), AT&T (T), AbbVie (ABBV), Alibaba Group (BABA) and Taiwan Semiconductor Manufacturing (TSM). Company Calendar Last Earnings7/30/2026Today10/27/2026Next Earnings (Estimated)10/29/2026Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 TAK's financial health is in the Green zone, according to TradeSmith. TAK has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:TAK CIK1395064 Webwww.takeda.com Phone+81332782111Fax813-3278-2268Employees47,000Year Founded1781Profitability EPS (Trailing Twelve Months)$0.34 Trailing P/E Ratio59.66 Forward P/E Ratio13.00 P/E GrowthN/ANet Income-$1.01 billion Net Margins3.80% Pretax Margin-3.16% Return on Equity10.95% Return on Assets5.34% Debt Debt-to-Equity Ratio0.58 Current Ratio1.14 Quick Ratio0.62 Sales & Book Value Annual Sales$28.32 billion Price / Sales2.29 Cash Flow$3.11 per share Price / Cash Flow6.52 Book Value$15.41 per share Price / Book1.32Miscellaneous Outstanding Shares3,204,280,000Free Float3,203,001,000Market Cap$65.00 billion OptionableOptionable Beta-0.07 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NYSE:TAK) was last updated on 10/27/2026 by MarketBeat.com Staff. From Our Partners80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredWould Anthropic IPO Burst the Bubble?The biggest IPO in history is likely just weeks away… Anthropic, the company behind Claude AI, is rumoured ...Crypto 101 Media | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredFirst Look: Elon’s “Starphone”Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to...Stansberry Research | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Takeda Pharmaceutical Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Takeda Pharmaceutical With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
